Drug Trial Radar · NCT07922798
A Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 29, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-center, randomized, double-blind, placebo-controlled, first-in-human, dose-escalation trial (with an open-label design for the first dose cohort), designed to evaluate the safety, tolerability, and PK/PD characteristics of UBT48128 tablets following single oral administration in healthy adult participants, the effect of food on the PK characteristics of UBT48128, the biotransformation and mass balance properties of UBT48128 in vivo, and its effect on the QT/QTc interval.
Conditions
- Overweight , Obesity
Interventions
UBT48128Drug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of adverse events (AEs), adverse drug reactions (ADRs), serious adverse events (SAEs), etc,..Time frame: Baseline to Day 6 and Day 13
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.